CP-101 is under clinical development by Finch Therapeutics Group and currently in Phase I for Ulcerative Colitis. According to GlobalData, Phase I drugs for Ulcerative Colitis have an 84% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how CP-101’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

CP-101 overview

CP-101 is under development for mild-to-moderate ulcerative colitis. It was under development for the treatment of autism spectrum disorder associated with gastrointestinal symptoms. The drug candidate is donor-derived fecal microbiota. It is formulated as capsule and is administered orally. It wa also under development for the treatment of chronic hepatitis B. 

It was also under development for the treatment of Clostridium difficile infections.

Finch Therapeutics Group overview

Finch Therapeutics Group (Finch) is a microbiome therapeutics company that discovers and develops biological drugs for gastrointestinal and neurological diseases. The company is investigating its lead product candidate CP101 for the treatment of recurrent clostridium difficile infection (CDI). It is also evaluating FIN-524 against ulcerative colitis; FIN-525 to treat Crohn’s disease and FIN-211; targeting autism spectrum disorder (ASD). Finch utilizes its proprietary Human-First Discovery platform technology to develop its therapies. The company also works in partnership with various pharmaceutical companies and other research institutions to develop microbiome therapeutics. Finch is headquartered in Somerville, Massachusetts, the US.

For a complete picture of CP-101’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.